文献速递免疫规划妇幼与学校卫生

轮状病毒疫苗加强剂进一步降低腹泻死亡率的潜力

Potential for a booster dose of rotavirus vaccine to further reduce diarrhea mortality.
PubMed 文献 · Vaccine · 2017-11-20

研究评估在9或12月龄与麻疹疫苗同时接种轮状病毒疫苗加强剂对降低轮状病毒死亡数的假想效益,基于国家免疫覆盖率、按周龄估计的轮状病毒死亡数和文献报告的疫苗有效性,假设三种免疫力消退模式并模拟三种加强情景,估计全球额外避免死亡数从中位数9800至29400不等,结果对免疫力消退函数形式高度敏感。

要点

  • 在阶梯式消退模型下,三种加强情景全球额外避免轮状病毒死亡中位数分别为9800、19600和29400。
  • 若免疫力呈线性或对数式消退,额外避免死亡数较阶梯式模型减少约65-80%。
  • 作者认为这些预测有助于考虑轮状病毒疫苗加强剂接种。

核心结论

  • 在阶梯式免疫力消退模型下,三种加强情景可额外避免轮状病毒死亡中位数分别为9800(95%CI:9400,10200)、19600(95%CI:18800,20400)和29400(95%CI:28200,30700)。
  • 这些估计对假设的免疫力消退函数形式高度敏感,若免疫力呈线性或对数式消退,额外避免死亡数较阶梯式模型减少约65-80%。
  • 作者认为这些预测将受益于改进的输入数据点,但结果有助于考虑轮状病毒疫苗加强剂接种。

研究设计与样本

  • 研究计算了在9或12月龄与麻疹疫苗同时接种轮状病毒疫苗加强剂的假想效益。
  • 使用国家层面全程接种覆盖率、按周龄估计的国家轮状病毒死亡数以及文献报告的<12月龄和≥12月龄疫苗有效性。
  • 基于疫苗有效性估计假设了阶梯式、线性和对数式三种免疫力消退函数形式。
  • 模拟了三种加强情景:a)第二年的疫苗有效性消退减少50%;b)将第二年疫苗有效性重建至第一年水平;c)将第一年疫苗有效性提升第一年与第二年有效性差值的50%。
  • 为表达参数不确定性,九个模型各使用输入值随机样本运行1000次。

主要发现

  • 在所有WHO区域,阶梯式模型下减少疫苗有效性消退、重建疫苗有效性和提升疫苗有效性三种情景的额外避免轮状病毒死亡中位数分别为9800(95%CI:9400,10200)、19600(95%CI:18800,20400)和29400(95%CI:28200,30700)。
  • 与阶梯式模型相比,若免疫力呈线性或对数式消退,额外避免死亡数减少约65-80%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 这些预测将受益于改进的输入数据点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Concern has grown that children vaccinated against rotavirus in developing countries may be vulnerable to rotavirus diarrhea in the second year of life due to waning immunity. Adding a booster dose of rotavirus vaccine at 9 or 12 months of age with measles vaccine has been suggested as a strategy to address this. We evaluated the hypothetical potential benefits of a booster dose on reduction of rotavirus mortality. The projected number of deaths averted were calculated using national level full series vaccination coverage, estimated national rotavirus deaths by week of age, and VE at <12 months of age and ≥12 months of age derived from the published literature. We assumed three functional forms of waning based on the VE estimates: stepwise, linear, and logarithmic. We modeled three potential boosting scenarios: (a) reduced VE waning in the second year of life by 50%, (b) reestablished second year of life VE to the levels in the first year of life, and (c) boosted first year VE by 50% of the difference between VE in the first and second years. To express uncertainty resulting from the parameters, each of the nine models were run 1000 times using a random sample of input values. Across all WHO regions, with the stepwise models we estimated a median of 9800 (95%CI: 9400, 10,200), 19,600 (95%CI: 18,800, 20,400), and 29,400 (95%CI: 28,200, 30,700) additional rotavirus deaths averted in the reduced VE waning, reestablished VE, and boosted VE scenarios. These estimates were highly sensitive to the assumed functional form of waning with approximately 65-80% fewer deaths averted if immunity waned in a linear or logarithmic fashion compared to the stepwise model. While these projections will benefit from improved input data points, our resultsinform consideration of booster doses of rotavirus vaccine.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Burnett E, Lopman BA, Parashar UD, et al. Potential for a booster dose of rotavirus vaccine to further reduce diarrhea mortality. Vaccine. 2017. PMID: 29169893. doi:10.1016/j.vaccine.2017.10.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。